Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis
Non-diabetic glomerulonephritis is a frequent cause of end-stage renal disease. The use of renin–angiotensin–aldosterone system blockers is a fundamental therapeutic approach. However, converting enzyme inhibi...